BR112017019921A2 - citalopram ou escitalopram para uso no tratamento de doenças neurodegenerativas. - Google Patents

citalopram ou escitalopram para uso no tratamento de doenças neurodegenerativas.

Info

Publication number
BR112017019921A2
BR112017019921A2 BR112017019921-1A BR112017019921A BR112017019921A2 BR 112017019921 A2 BR112017019921 A2 BR 112017019921A2 BR 112017019921 A BR112017019921 A BR 112017019921A BR 112017019921 A2 BR112017019921 A2 BR 112017019921A2
Authority
BR
Brazil
Prior art keywords
escitalopram
citalopram
treatment
neurodegenerative diseases
derivatives
Prior art date
Application number
BR112017019921-1A
Other languages
English (en)
Inventor
Espinheira De Sá Maciel Patrícia
Cristiana Teixeira De Castro Andreia
Luísa Jales Monteiro De Sousa Ana
Sofia Teixeira Esteves Ana
Jorge Carvalho Sousa Nuno
Original Assignee
Universidade Do Minho
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidade Do Minho filed Critical Universidade Do Minho
Publication of BR112017019921A2 publication Critical patent/BR112017019921A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

citalopram ou escitalopram para uso no tratamento de doenças neurodegenerativas. citalopram ou escitalopram, seus sais farmacêuticamente aceitáveis ou seus derivados para utilização no tratamento de doenças neurodegenerativas. o objeto da presente divulgação está relacionado ao uso de citalopram ou escitalopram, seus sais farmacêuticamente aceitáveis ou seus derivados, no tratamento de doenças neurodegenerativas que são positivamente influenciadas pela diminuição do desdobramento e / ou agregação de proteínas, em particular pela administração oral.
BR112017019921-1A 2015-03-17 2016-03-17 citalopram ou escitalopram para uso no tratamento de doenças neurodegenerativas. BR112017019921A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PT108294 2015-03-17
PT10829415 2015-03-17
PCT/IB2016/051511 WO2016147146A1 (en) 2015-03-17 2016-03-17 Citalopram or escitalopram for use in the treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
BR112017019921A2 true BR112017019921A2 (pt) 2018-06-19

Family

ID=56919750

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017019921-1A BR112017019921A2 (pt) 2015-03-17 2016-03-17 citalopram ou escitalopram para uso no tratamento de doenças neurodegenerativas.

Country Status (10)

Country Link
US (1) US11033526B2 (pt)
EP (3) EP3069718A1 (pt)
JP (1) JP6895893B2 (pt)
CN (1) CN107530314B (pt)
AU (1) AU2016231834A1 (pt)
BR (1) BR112017019921A2 (pt)
CA (1) CA2980135A1 (pt)
DK (1) DK3270913T3 (pt)
PT (1) PT3270913T (pt)
WO (1) WO2016147146A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023212231A1 (en) * 2022-04-27 2023-11-02 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200812993A (en) * 2006-05-02 2008-03-16 Lundbeck & Co As H New uses of escitalopram
US20130296183A1 (en) * 2010-09-17 2013-11-07 President And Fellows Of Harvard College Functional genomics assay for characterizing pluripotent stem cell utility and safety
EP2931274A1 (en) * 2012-12-11 2015-10-21 Metabolic Solutions Development Company LLC Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
EP3069718A1 (en) 2016-09-21
CA2980135A1 (en) 2016-09-22
JP6895893B2 (ja) 2021-06-30
DK3270913T3 (da) 2020-10-19
CN107530314B (zh) 2021-08-17
AU2016231834A1 (en) 2017-11-09
CN107530314A (zh) 2018-01-02
PT3270913T (pt) 2020-11-23
US11033526B2 (en) 2021-06-15
EP3270913B1 (en) 2020-07-15
US20190029992A1 (en) 2019-01-31
EP3270913A1 (en) 2018-01-24
EP3747434A1 (en) 2020-12-09
WO2016147146A1 (en) 2016-09-22
JP2018508558A (ja) 2018-03-29

Similar Documents

Publication Publication Date Title
CY1123845T1 (el) Τοπικα φαρμακευτικα σκευασματα για την αγωγη φλεγμονωδων καταστασεων
EA201591887A1 (ru) Макроциклические деазаоксипурины для лечения вирусных инфекций
EA201591524A1 (ru) Производные 2-аминопиримидина для лечения вирусных инфекций
BR112017021245A2 (pt) Anticorpo anti-c-met e conjugado anticorpo anti- c-met-fármaco citotóxico e uso farmacêutico do mesmo
BR112018077457A2 (pt) composição farmacêutica para evitar ou tratar hiperinsulinismo congênito e seu método, hipoglicemia e seu método, síndrome metabólica e seu método e peptídeo isolado
BR112018069601A2 (pt) derivados de indolina substituídos como inibidores da replicação viral da dengue
BR112017003346A2 (pt) derivados de pirazolopiridina, seus usos, e composição farmacêutica
EA202090683A3 (ru) Способы и композиции для лечения рака
BR112017009552A2 (pt) métodos para alvejar o controle transcricional em regiões de super-realçador
BR112018015718A2 (pt) utilização de estimuladores de sgc para o tratamento de esteato-hepatite não alcoólica (nash)
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
BR112019005329A2 (pt) composições de oligossacarídeos de leite humano purificadas
BR112016016870A8 (pt) derivados de icariina, seus usos, e composição farmacêutica
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112015001096A2 (pt) derivados de di e tri-heteroaril como inibidores de agregação de proteína
MX2016008397A (es) Composicion para usarse en el tratamiento de tos persistente.
DOP2018000049A (es) Compuestos para uso en aplicaciones antibacterianas
BR112016027383A8 (pt) derivados de naftiridinadiona, seus usos, composição farmacêutica e combinação
BR112017004580A2 (pt) composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
BR112016007238A2 (pt) tienouracilcarboxamidas cíclicas e sua utilização
UA118474C2 (uk) (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
BR112017024126B8 (pt) Composições farmacêuticas, composto a micronizado e/ou pelo menos um sal farmaceuticamente aceitável micronizado do composto a e uso dos mesmos
BR112014024033A8 (pt) Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes
EA201592242A1 (ru) Производные пиридона для лечения вирусных инфекций и других заболеваний

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2714 DE 10-01-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.